bioRxivMicrobiologyPreprint
Common biological features of Mycobacterium tuberculosis MmpL3 inhibitors
Lauren Ames, R. H. Allen, Helena I. BoshoffiD, Laura A. T. CleghorniD, Curtis A. EngelhartiD, Dirk SchnappingeriD, Tanya ParishiD
- Citations
- 1
Abstract
MmpL3 is a promising new target for antitubercular drugs, but the microbiological properties of MmpL3 inhibitors are not fully understood. We compared the activity and mode of action of 11 structurally diverse compound series that target MmpL3. We confirmed activity was via MmpL3 using strains with differential expression of MmpL3. MmpL3 inhibitors had potent activity against replicating M. tuberculosis, with increased activity against intramacrophage bacilli and were rapidly bactericidal. MmpL3 inhibition induced cell wall stress concomitantly with a boost in ATP levels in M. tuberculosis. Mutation in MmpL3 conferred resistance to all series at different levels. Molecules did not negatively impact membrane potential, pH homeostasis or induce reactive oxygen species and were inactive against starved bacilli. Our study revealed common features related to the chemical inhibition of MmpL3, enabling the identification of off-target effects and highlighting the potential of such compounds as future drug candidates.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of new MmpL3 inhibitors by untargeted and targeted mutant screens defines MmpL3 domains with differential resistance
J. T. Williams, E. R. Haiderer, … R. B. Abramovitch·bioRxiv·Feb 28, 2019
- Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis
Vanessa Pietrowski Baldin, Christopher L. Harding, … Tanya Parish·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 22, 2025
- Inoculum-dependent bactericidal activity of a Mycobacterium tuberculosis MmpL3 inhibitor
B. Berube, A. Deshpande, … T. Parish·bioRxiv·Feb 22, 2023
- Repurposing ethacridine as a potent MMPL3 Inhibitor for the treatment of tuberculosis
Puja Kumari Agnivesh, Arnab Roy, … Nitin Pal Kalia·bioRxiv·Nov 25, 2025
- An arylsulphonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis
R. H. Allen, Lauren Ames, … Tanya Parish·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 26, 2024
- A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis
M. Li, H. V. Patel, … J. C. Seeliger·bioRxiv·Apr 16, 2021